- Home
- CERO vs GLMD Comparison
CERO vs GLMD Comparison
Compare CERO & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- GLMD
- Stock Information
- Founded
- CERO 2017
- GLMD 2000
- Country
- CERO United States
- GLMD Israel
- Employees
- CERO N/A
- GLMD N/A
- Industry
- CERO
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- CERO
- GLMD Health Care
- Exchange
- CERO Nasdaq
- GLMD Nasdaq
- Market Cap
- CERO 3.5M
- GLMD 3.0M
- IPO Year
- CERO N/A
- GLMD 2014
- Fundamental
- Price
- CERO $9.18
- GLMD $1.78
- Analyst Decision
- CERO Strong Buy
- GLMD Hold
- Analyst Count
- CERO 2
- GLMD 1
- Target Price
- CERO $45.00
- GLMD N/A
- AVG Volume (30 Days)
- CERO 3.3M
- GLMD 347.2K
- Earning Date
- CERO 08-13-2025
- GLMD 05-22-2025
- Dividend Yield
- CERO N/A
- GLMD N/A
- EPS Growth
- CERO N/A
- GLMD N/A
- EPS
- CERO N/A
- GLMD N/A
- Revenue
- CERO N/A
- GLMD N/A
- Revenue This Year
- CERO N/A
- GLMD N/A
- Revenue Next Year
- CERO N/A
- GLMD N/A
- P/E Ratio
- CERO N/A
- GLMD N/A
- Revenue Growth
- CERO N/A
- GLMD N/A
- 52 Week Low
- CERO $6.71
- GLMD $1.15
- 52 Week High
- CERO $895.40
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- CERO 46.88
- GLMD 61.10
- Support Level
- CERO $8.12
- GLMD $1.63
- Resistance Level
- CERO $11.68
- GLMD $1.91
- Average True Range (ATR)
- CERO 2.74
- GLMD 0.12
- MACD
- CERO 0.14
- GLMD 0.01
- Stochastic Oscillator
- CERO 12.04
- GLMD 71.22
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.